Cytomegalovirus human immunoglobulin

CLINICAL USE

Prophylaxis for renal transplant recipients at risk of primary cytomegalovirus (CMV) diseaseTreatment of CMV disease (usually with ganciclovir)

DOSE IN NORMAL RENAL FUNCTION

See local protocols

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :150

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :N/A

%Excreted unchanged in urine &nbsp &nbsp : 0

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :50

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsCiclosporin: no effect on efficacy of CMV immunoglobulin

ADMINISTRATION

Reconstition

–

Route

IV peripherally or centrally

Rate of Administration

–

Comments

Follow guidelines supplied by company

OTHER INFORMATION

Can give 10 mg IV chlorphenamine 1 hour before administrationMonitor for anaphylaxis, have epinephrine availableDo not mix with any other drugs or infusion fluids

Tags: post-by-auto-php